Eric B. Kmiec

Eric B. Kmiec has a strong background in scientific research and leadership roles. Currently, they hold the positions of Chief Executive Officer and Scientific Founder at CorriXR Therapeutics since March 2022. Eric previously worked at ChristianaCare from 2015 to 2022, first as the Executive Director and Chief Scientific Officer of the Gene Editing Institute, and later as the Director of the Gene Editing Institute until April 2022. Additionally, they were an Affiliated Faculty at the University of Delaware since 2015. Prior to that, they served as a Professor and Chairman of the Chemistry Department at Delaware State University from 2011 to 2015. Eric was also involved in co-founding and serving as the Chief Scientific Officer and Board Member at OrphageniX from 2005 to 2013. Kmiec has held various academic positions, including as an Eminent Scholar and Director at the Marshall Institute for Interdisciplinary Research at Marshall University from 2009 to 2011, a Professor at the University of Delaware from 1999 to 2008, and an Associate Professor at Thomas Jefferson University from 1990 to 1999. Eric also served as the Chief Scientific Advisor at Tapestry Pharmaceuticals, Genomics Division from 1999 to 2005, and as the Founder, Consultant, and Vice President of Molecular Biology at Kimeragen, Inc. from 1994 to 1998.

Eric B. Kmiec holds a Ph.D. in Molecular Biology/Biochemistry from the University of Florida, which they obtained in 1984. Prior to that, they completed an MS in Cell Biology/Biochemistry at Southern Illinois University Edwardsville in 1980. In 1978, Eric earned a BA in Microbiology from Rutgers University.